From counterculture to center-stage, alternative medical treatments, particularly psychedelics, have come a very long way in just a few years. It's amazing to think that today, a research landmark like Johns Hopkins University is lending credence to the idea that psychedelic solutions are the future of medicine.

But that's exactly what's happening in what could be the most exciting recent development to happen in the field of mental health. At the Joseph V. Brady Behavioral Biology Research Center at Johns Hopkins, the psychedelic drug psilocybin has been used in experiments to treat depression.

The results are absolutely eye-opening, as Johns Hopkins treated 360 patients for their depression. The research found that their depression was, in many cases, lifted for months just from a treatment session or two.

Just as importantly, this is happening in a safe and controlled manner. This isn't the 'party drug' of past generations, where people would take drugs illegally in the pursuit of a good time. This time, it's bona fide clinical pharmacology research that's done in the name of potentially helping millions of patients suffering from mood disorders, anxiety, addiction, and more.

This is a boon to the community, but it's also bringing attention and capital to clinics and companies focused on leveraging the power of psychedelic medical components like psilocybin and ketamine. Among the best-performing companies in this space are the ones that can develop and commercialize research-backed, psychedelic-based medical solutions.

The prime example of this today is a company called Champignon Brands (CSE: SHRM, OTC: SHRMF), which has a tradable stock and a leading psychedelic research clinic known as the Canadian Rapid Treatment Centre of Excellence, or CRTCE.

Champignon's flagship clinic, located in Mississauga, Ontario, is fully operational and provides vast competitive advantages:

  • 16 months of operating history
  • It's currently the only Health Canada-approved clinic to conduct randomized controlled trials (RCTs) for psilocybin
  • Roughly $1,000,000 in revenue in the first full year of operations
  • Over 1,500 ketamine treatments administered and over 300 patients serviced to date
  • Colocated pharmacy with an agreement in place

A clinical center like this is massively de-risked because it is cash-flow positive. This methodology enables the company to bypass the CROs (contract research organizations), therefore shrinking the time to commercialization from 5 years to potentially 18 months.

That's a huge relief for all the patients suffering from depression and who don't want to take their old, ineffective, potentially addictive prescription medications. Champignon Brands and the CRTCE plan to more efficiently develop and bring novel treatments to the market for individuals struggling with depression, PTSD, and substance abuse disorders.

This way, Champignon can expand the company's already considerable clinical footprint in the area of behavioral health. As capital flows in, the CRTCE seeks to establish new treatments and patents, along with pharmaceutical industry partnerships for ketamine and psilocybin.


Consider becoming a shareholder of Champignon Brands (CSE: SHRM, OTC: SHRMF))

For further updates on Champignon Brands, subscribe now!

    We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. You should know that we have been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies' SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

    Please read our full disclaimer at